Blue­print Med­i­cines nabs 4th ap­proval in bid to­ward prof­itabil­i­ty

Blue­print Med­i­cines’ push to prof­itabil­i­ty con­tin­ues.

On Wednes­day, the Cam­bridge biotech an­nounced the FDA ap­proved its long­time lead drug, Ay­vak­it, for ad­vanced sys­temic mas­to­cy­to­sis, a group of de­bil­i­tat­ing rare dis­eases where one type of im­mune cell — mast cells — builds up un­con­trol­lably in a par­tic­u­lar or­gan. The de­ci­sion came on the heels of Phase III tri­als show­ing that more than half of late-stage pa­tients who re­ceived the drug re­spond­ed to it and did so for just over three years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER